Ervin Anaya, MD
Pulmonary Disease · Louisville, KYNPI 1841337219
Payments from drug & device makers
Across 359 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$941
- GSK$858
- AstraZeneca$801
- Pfizer$729
- Mylan Specialty L.p.$598
- Grifols USA, LLC$412
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,81299%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 33 | $941 |
| GSK | 66 | $858 |
| AstraZeneca | 35 | $801 |
| Pfizer | 40 | $729 |
| Mylan Specialty L.p. | 32 | $598 |
| Grifols USA, LLC | 23 | $412 |
| Insmed, Inc. | 28 | $401 |
| Actelion Pharmaceuticals US, Inc. | 7 | $257 |
| Sanofi | 9 | $195 |
| Novartis | 7 | $153 |
| Teva Pharmaceuticals USA, Inc. | 9 | $138 |
| Pulmonx Corporation | 1 | $126 |
| Sunovion Pharmaceuticals Inc. | 10 | $125 |
| Amgen | 7 | $123 |
| Lilly USA, LLC | 3 | $122 |
| Regeneron Healthcare Solutions, Inc. | 5 | $121 |
| Merck | 6 | $94 |
| Genentech USA, Inc. | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| CSL Behring | 3 | $56 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $44 |
| United Therapeutics Corporation | 2 | $36 |
| Verona Pharma, Inc. | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Shire North American Group Inc | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Pinnacle Biologics, Inc | 1 | $25 |
| Chiesi USA, Inc. | 1 | $24 |
| Abbott | 1 | $21 |
| Viatris Specialty LLC | 1 | $21 |
| Bayer | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| AbbVie | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Ambu Inc. | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Electromed, Inc. | 1 | $12 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STIOLTO RESPIMAT$242
- SPIRIVA RESPIMAT$242
- Pulmonx Endobronchial Valve EBV$126
- OFEV$122
- UPTRAVI$121
- OPSUMIT$121
How this compares
$6,878 in reported general payments places this provider in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 53 | $670,626 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 665 | $508,659 |
| TezspireTezepelumab-Ekko | 36 | $151,416 |
| Breo ElliptaFluticasone/Vilanterol | 254 | $117,717 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $65,335 |
| Dupixent PenDupilumab | 13 | $56,783 |
| Spiriva RespimatTiotropium Bromide | 54 | $38,338 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $30,409 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $23,498 |
| Arnuity ElliptaFluticasone Furoate | 91 | $21,035 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $20,050 |
| Pirfenidone | 11 | $15,497 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $14,781 |
| Spiriva HandihalerTiotropium Bromide | 21 | $13,790 |
| Formoterol Fumarate | 12 | $11,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $941 | $741,699160 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $858 | $688,5401,088 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $801 | $241,425177 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $257 | $6,10912 claims |
| MerckDulera | $94 | $5,51215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$3.5M
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Samantha BaahLouisville$226K
- Lebnan SaadLouisville$105K
- Josephine MeiLouisville$101K
- Tanya WieseLouisville$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.